CYP3A4/P-glycoprotein inhibitors related colchicine toxicity mimicking septic shock

被引:0
|
作者
Ngeyvijit, Jinjuta [1 ]
Nuansuwan, Sopita [2 ]
Phoophiboon, Vorakamol [3 ,4 ]
机构
[1] Chaophraya Abhaibhubejhr Hosp, Dept Med, Div Pulm & Crit Care Med, Prachin Buri, Thailand
[2] Chaophraya Abhaibhubejhr Hosp, Dept Med, Prachin Buri, Thailand
[3] Chulalongkorn Univ, Fac Med, Dept Med, Div Crit Care Med, Bangkok, Thailand
[4] Univ Toronto, St Michaels Hosp, Div Crit Care Med, Unity Hlth Toronto, Toronto, ON, Canada
关键词
Drug interactions; Adult intensive care; Toxicology; AMERICAN-COLLEGE; INTOXICATION; MANAGEMENT; CLARITHROMYCIN; OVERDOSE; RECOMMENDATIONS; GUIDELINE; DRUGS;
D O I
10.1136/bcr-2023-257186
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Colchicine toxicity is uncommon when patients receive a therapeutic dose regularly. However, inadvertent drug interactions can result in unpredicted adverse outcomes. The toxicity of colchicine can manifest in various ways, ranging from mild and non-specific symptoms to severe form known as multiple organ dysfunction syndrome. This case highlights (1) the diagnostic challenge that arises when distinguishing between the severe manifestation of colchicine toxicity and septic shock and (2) concomitant prescription of colchicine with potent CYP3A4 and P-glycoprotein inhibitors (ie, clarithromycin) can lead to colchicine toxicity despite normal renal and hepatic clearance. Unfortunately, specific tests of colchicine toxicity were not routinely available. A high index of clinical suspicion and recognition of drug interactions with their common presentations are crucial for making diagnosis and management. Failure to recognise drug toxicity can result in poor outcomes.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach
    Ito, K
    Kusuhara, H
    Sugiyama, Y
    PHARMACEUTICAL RESEARCH, 1999, 16 (02) : 225 - 231
  • [22] Effects of Intestinal CYP3A4 and P-Glycoprotein on Oral Drug Absorption—Theoretical Approach
    Kiyomi Ito
    Hiroyuki Kusuhara
    Yuichi Sugiyama
    Pharmaceutical Research, 1999, 16 : 225 - 231
  • [23] Crohn's Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression
    Wilson, Aze
    Urquhart, Bradley L.
    Ponich, Terry
    Chande, Nilesh
    Gregor, James C.
    Beaton, Melanie
    Kim, Richard B.
    MOLECULAR PHARMACEUTICS, 2019, 16 (09) : 4059 - 4064
  • [24] Modulation of P-glycoprotein and cytochrome P450(CYP3A4) by extracts of Turnera diffusa leaves
    Sinha, S. D.
    Harle, U. N.
    Gaikwad, N. J.
    INDIAN JOURNAL OF PHARMACOLOGY, 2008, 40 : 93 - 93
  • [25] Effects of the Strong CYP3A4 and P-glycoprotein Inhibitor Itraconazole on the Pharmacokinetics of Oral and Intranasal Zavegepant
    Bhardwaj, Rajinder
    Malatesta, Jo Ann
    Stringfellow, Joseph
    Madonia, Jennifer
    Anderson, Matt
    Morris, Beth
    Coric, Vladimir
    Croop, Robert
    Bertz, Richard
    NEUROLOGY, 2023, 100 (17)
  • [26] Colchicine and CYP3A4/P-gp inhibitors interaction signal detection using FAERS
    Gomez-Lumbreras, Ainhoa
    Boyce, Richard D.
    Zapata, Lorenzo Villa
    Hansten, Philip D.
    Malone, Daniel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 172 - 172
  • [27] Serum Rifampicin Levels in Patients with TuberculosisEffect of P-Glycoprotein and CYP3A4 Blockers on its Absorption
    Jai Prakash
    Thirumurthy Velpandian
    Jitender N. Pande
    Suresh K. Gupta
    Clinical Drug Investigation, 2003, 23 : 463 - 472
  • [28] Predicting Drug-Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein
    Tachibana, Tatsuhiko
    Kato, Motohiro
    Takano, Junichi
    Sugiyama, Yuichi
    CURRENT DRUG METABOLISM, 2010, 11 (09) : 762 - 777
  • [29] Effects of the strong CYP3A4 and P-glycoprotein inhibitor itraconazole on the pharmacokinetics of oral and intranasal zavegepant
    Bhardwaj, R.
    Malatesta, J. K.
    Stringfellow, J.
    Madonia, J.
    Anderson, M.
    Stock, D. A.
    Morris, B. A.
    Coric, V
    Croop, R.
    Bertz, R.
    HEADACHE, 2022, 62 : 140 - 141
  • [30] P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability
    Martinez-Chavez, Alejandra
    van Hoppe, Stephanie
    Rosing, Hilde
    Lebre, Maria C.
    Tibben, Matthijs
    Beijnen, Jos H.
    Schinkel, Alfred H.
    MOLECULAR PHARMACEUTICS, 2019, 16 (09) : 3842 - 3852